



## About HeartSciences™

*Advancing Early Detection of Cardiac Disease*

---

### WHO IS HEARTSCIENCES:

- Incorporated in 2007, **HeartSciences** (formerly known as Heart Test Laboratories) is a **privately held medical technology company** located in the Dallas-Fort Worth metroplex. HeartSciences was formed to develop improvements in electrocardiography using advanced signal processing. For a decade, HeartSciences has been dedicated to the development of accurate, affordable cardiac testing tools for the early detection of heart disease.
  - To date, HeartSciences has invested more than **\$30 million in research and development (R&D)** in an effort to fundamentally improve the sensitivity of an electrocardiograph (ECG/EKG) for the early detection of heart disease. The ECG is a device that has not experienced significant clinical advancement in decades, until now.
  - HeartSciences is led by CEO Mark Hilz and Chairman Andrew Simpson, **seasoned entrepreneurs with more than 50 years of combined experience** building successful start-up companies and growing both private and public companies.
- 

### THE HEART OF HEARTSCIENCES:

- HeartSciences lead innovation is the **MyoVista® high sensitivity ECG (hsECG™) Cardiac Testing Device**, the industry's first electrocardiographic device that applies proprietary use of **Continuous Wavelet Transform (CWT) signal processing technology**.
  - MyoVista hsECG uses the same 12-lead, at-rest testing protocol as traditional ECG devices on the market today to help facilitate easy adoption for clinical staff.
    - The difference is that MyoVista is a single test that provides healthcare practitioners with **unique informatics**, as well as conventional 12-lead resting ECG tracings and conventional ECG interpretive analysis.
    - In combination, these assist identification of cardiac dysfunction related to CAD and structural disease, as well as identifying arrhythmias.
  - The MyoVista hsECG device **has CE Mark #CE656481, which allows commercial sale and clinical use of the device in the European Union (EU)**, as well as a number of other territories around the world. The device is not currently available for sale or use in the United States, HeartSciences expects to seek U.S. Food and Drug Administration clearance for the MyoVista in 2018.
-

## OUR HISTORY:

### 2007

- Heart Test Labs formed as Texas-based C corporation to fund development of a modern electrocardiographic device using advanced signal processing

### 2008-2012

- Secured early funding of \$8 million
- R&D spending included development of early prototype device
- Early proof of concept clinical studies
- Patent granted on overall unit, July 2012

### 2013-2016

- Management transitioned to experienced operational team to complete R&D and focus on commercialization
- Initiated clinical studies at Mount Sinai Hospital in New York and Windsor Cardiac Centre in Canada
- Completed final device design and submitted for CE Mark
- \$23 million in further equity funding capital raised for continued R&D as well funding initial production and sales

### 2017

- Company name changed to HeartSciences to more clearly articulate our mission of applying proven science to provide accurate, affordable screening tools for the early detection of heart disease
- Fundamental signal processing patent granted
- MyoVista received CE Mark (Conformité Européen) for commercial sale and clinical use in the EU and begins registration in many other territories around the world
- Completed 200 patient validation trial at Mount Sinai Hospital, NY with significant results in detecting cardiac (diastolic) dysfunction with 88% sensitivity and 87% specificity
- Recruitment of distribution partners begins
- Initial Orders received

For more information about HeartSciences, please visit our website [www.heartsciences.com/contact](http://www.heartsciences.com/contact).

<sup>1</sup> United States Department of Commerce, Bureau of Economic Analysis, 2015. Available at: [https://www.bea.gov/newsreleases/regional/gdp\\_metro/2016/pdf/gdp\\_metro0916.pdf](https://www.bea.gov/newsreleases/regional/gdp_metro/2016/pdf/gdp_metro0916.pdf).